



## NYSE Euronext welcomes STENTYS to its European market

Paris, 25 October 2010 – STENTYS, a medical-technology company pioneering the development of innovative stents<sup>1</sup>, today celebrated its listing on NYSE Euronext in Paris under the ticker symbol “STNT”.

Founded in 2006, STENTYS builds on close collaboration with leading cardiologists in Europe and North America to develop innovative solutions for the treatment of myocardial infarction, designing and distributing self-expanding stents that take the shape of the artery and adapt to the complexities of coronary anatomy with lateral opening for arterial bifurcation. In 2010, its stents won CE marking<sup>2</sup>, allowing sales throughout the European Union.

STENTYS was listed through the admission to trading on the regulated market of NYSE Euronext in Paris of the 5,353,793 existing shares making up its capital and 1,893,939 new shares as part of a Global Offering<sup>3</sup>, before exercise of the over-allotment option. The company raised a total of €22.7 million. On the basis of the admission price of €12 per share, its market capitalization stands at €87 million.

*"We are delighted to welcome STENTYS to our European market and see businesses with cutting-edge expertise in areas such as medical technology continuing to look to the market to finance expansion," comments Ronald Kent, Group Executive Vice President and Head of International Listings at NYSE Euronext. "We look forward to a beneficial and lasting partnership and to providing STENTYS and its shareholders with the highest levels of service, liquidity and brand visibility associated with listing on our markets."*

Gonzague Issenmann, Chief Executive Officer of STENTYS added: *"We are very pleased with the success of STENTYS' IPO. We would like to thank all our shareholders for their support and their confidence."*

Jacques Séguin, Chairman and Co-Founder of STENTYS said: *"Our innovative technology convinced the investors. We now have the means to establish STENTYS' self-apposing stent as the reference treatment for heart attack, a \$2.3 billion market."*



<sup>1</sup> Tubular metal-mesh devices inserted into arteries and other body cavities to keep them open.

<sup>2</sup> CE marking is required for all products subject to regulation under one or more European Directives, concerning in particular safety, public health and consumer protection. The marking attests compliance with the essential requirements of applicable Directives.

<sup>3</sup> The Global Offering was made up of an Open Price Offering and a Global Placement with institutional investors in France and other countries to the exclusion of the United States.

## **Press contacts**

### **NYSE Euronext**

Caroline Tourrier: +33 (0)1 49 27 10 82 – [ctourrier@nyx.com](mailto:ctourrier@nyx.com)

### **STENTYS**

#### **Citigate Dewe Rogerson**

Agnès Villeret: +33 (0)1 53 32 78 95 – [agnes.villeret@citigate.fr](mailto:agnes.villeret@citigate.fr)

### **About NYSE Euronext**

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group.

NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's secondlargest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the S&P 100 index and Fortune 500. For more information, please visit: [www.nyx.com](http://www.nyx.com)

### **About STENTYS**

Based in Paris (France) and Princeton, N.J. (USA), the STENTYS Company has developed a new generation of stents to treat acute myocardial infarction. Founded by Jacques Séguin, Professor of Cardiac Surgery, and Gonzague Issenmann, STENTYS received the CE mark for its flagship products in 2010. Its self-apposing stents adapt the anatomic changes of the arteries in the post-infarction phase and prevents conventional stents mal-apposition problems. STENTYS has started its marketing activities in several European countries.